Abstract:Somatic cell nuclear transfer (SCNT) has been proved capable of reprogramming various differentiated somatic cells into pluripotent stem cells. Recently, induced pluripotent stem cells (iPS) have been successfully derived from mouse and human somatic cells by the over-expression of a combination of transcription factors. However, the molecular mechanisms underlying the reprogramming mediated by either the SCNT or iPS approach are poorly understood. Increasing evidence indicates that many tumor pathways play roles in the derivation of iPS cells. Embryonal carcinoma (EC) cells have the characteristics of both stem cells and cancer cells and thus they might be the better candidates for elucidating the details of the reprogramming process. Although previous studies indicate that EC cells cannot be reprogrammed into real pluripotent stem cells, the reasons for this remain unclear. Here, nuclei from mouse EC cells (P19) were transplanted into enucleated oocytes and pluripotent stem cells (P19 NTES cells) were subsequently established. Interestingly, P19 NTES cells prolonged the development of tetraploid aggregated embryos compared to EC cells alone. More importantly, we found that the expression recovery of the imprinted H19 gene was dependent on the methylation state in the differential methylation region (DMR). The induction of Nanog expression, however, was independent of the promoter region DNA methylation state in P19 NTES cells. A whole-genome transcriptome analysis further demonstrated that P19 NTES cells were indeed the intermediates between P19 cells and ES cells and many interesting genes were uncovered that may be responsible for the failed reprogramming of P19 cells. To our knowledge, for the first time, we linked incomplete reprogramming to the improved pluripotency of EC cell-derived pluripotent stem cells. The candidate genes we discovered may be useful not only for understanding the mechanisms of reprogramming, but also for deciphering the transition between tumorigenesis and pluripotency.

Genome integrity: linking pluripotency and tumorgenicity.

p53 and stem cells: new developments and new concerns.

P53 and Stem Cells: New Developments and New Concerns

Functions of P53 in Pluripotent Stem Cells

The genomic stability of induced pluripotent stem cells

Relationship Between Regulatory Pathways in Pluripotent Stem Cells and Human Tumors

The Propensity for Tumorigenesis in Human Induced Pluripotent Stem Cells is Related with Genomic Instability.

Progress and Bottleneck in Induced Pluripotency.

The role of p53 in the transformation of induced pluripotent stem cells to tumor cells

The Emerging Roles of Oct4 in Tumor-Initiating Cells.

The role of lipids in genome integrity and pluripotency

A New Role for P53 in Maintaining Genetic Stability in Embryonic Stem Cells

At a Crossroads to Cancer: How p53-Induced Cell Fate Decisions Secure Genome Integrity

Molecular Mechanisms of Pluripotency and Reprogramming

DNA Damage Response and Cell Cycle Regulation in Pluripotent Stem Cells

p53 isoform Δ133p53 promotes efficiency of induced pluripotent stem cells and ensures genomic integrity during reprogramming

Possible Strategies to Reduce the Tumorigenic Risk of Reprogrammed Normal and Cancer Cells

P53 Isoform Delta 133p53 Promotes Efficiency Of Induced Pluripotent Stem Cells And Ensures Genomic Integrity During Reprogramming

Increase Developmental Plasticity Of Human Keratinocytes With Gene Suppression

Context‐Dependent Enhancement of Induced Pluripotent Stem Cell Reprogramming by Silencing Puma

Linking Incomplete Reprogramming to the Improved Pluripotency of Murine Embryonal Carcinoma Cell-Derived Pluripotent Stem Cells